MDNA-223, a novel anti-PD1-IL-2 BiSKIT candidate with efficacy in both cold and hot tumor models
Oct. 5, 2023
A presentation given recently by Medicenna Therapeutics Corp. highlighted preclinical data for the company’s new anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy) candidate, MDNA-223, being developed as a anticancer therapeutic candidate.
